Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginase Inhibition in Ischemia-reperfusion Injury
NCT02009527Phase 1Completed
- Sponsor
- Karolinska Institutet
- Start
- Jan 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of n-hydroxy-nor-l-arginine in ischemia-reperfusion injury (IRI) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Change in endothelial function. Started Jan 2012; status: completed.
02
Drugs
n-hydroxy-nor-l-arginine
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02009527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009527.